Noll L. Campbell
Faculty Associate, Center on Center on Aging and Life Course
2004 Geriatric Specialty Residency, University of North Carolina Hospitals
2003 Pharmacy Practice Residency, St. Vincent Hospital and Health Services
2002 PharmD, Butler University
As an investigator with the Regenstrief Institute and the Indiana University Center for Aging Research, Dr. Campbell’s research focuses on both acute and chronic adverse cognitive effects of medications, including research related to delirium and dementia. He also conducts research on barriers and interventions for medication adherence among older adults with or at risk of cognitive impairment. He has conducted pharmacoepidemiologic and qualitative research, as well as randomized controlled trials. Dr. Campbell has received support for his research from the National Institutes of Health, Astellas, and Merck and Co.
Service and Engagement
PHRM 495: Independent Study
PHRM 699: Independent Study
President, American Delirium Society, 2023-2024
Member, Conference Planning Committee, American Geriatrics Society, 2018-2021
Honors and Credentials
2021 Chaney Family Early Faculty Scholar
2019 Department Best Paper Award
2015 Charleston Conference for Alzheimer’s disease
2014 Tony & Mary Hulman Award for Achievement in Geriatrics, Indiana Public Health Association
2012 Merck/American Geriatrics Society New Investigator Award
1. Campbell NL, Holden RJ, Tang Q, Boustani MA, Teal E, Hillstrom J, Tu W, Clark DO, Callahan CM. Multi-component behavioral intervention to reduce exposure to anticholinergics in primary care older adults. J Amer Geriatr Soc 2021; 2021 Mar 26. doi: 10.1111/jgs.17121. Online ahead of print..
2. Campbell NL, Holden R, Boustani MA. Preventing Alzheimer Disease by deprescribing anticholinergic medications. JAMA Intern Med 2019 Jun; 179(8):1084-1093. doi: 10.1001/jamainternmed.2019.0676. PMID: 31233087.
3. Campbell NL, Perkins AJ, Khan BA, Gao S, Farber MO, Boustani MA. Deprescribing in the Pharmacologic Management of Delirium (de-PMD): A Randomized Trial in the Intensive Care Unit. J Am Geriatr Soc 2019 Apr;67(4):695-702. Doi:10.1111/jgs.15751.
4. Campbell NL, Lane KA, Gao S, Boustani M, Unverzagt F. Anticholinergics increase transition from normal cognition to mild cognitive impairment in community-dwelling older adults. Pharmacotherapy 2018 May;38(5):511-519. doi: 10.1002/phar.2106. Epub 2018 Apr 25. PMID: 29600808. https://doi.org/10.1002/phar.2106.
5. Campbell NL, Perkins AP, Gao S, Skaar TC, Li L, Hendrie HC, Fowler N, Callahan CM, Boustani MA. Adherence and tolerability of Alzheimer’s disease medications: a pragmatic randomized trial. J Am Geriatri Soc 2017;65(7):1497-1504.
6. Campbell NL, Unverzagt F, Lamantia MA, Khan BA, Boustani MA. Risk factors for progression of early cognitive impairment to dementia. Clin Geri Med.2013. 29 (4), 873-893.
7. Campbell NL, Zhan J, Tu W, Weber Z, Ambeuhl R, McKay C, McElwee N. Self-Reported Medication Adherence Barriers among Ambulatory Older Adults with Mild Cognitive Impairment. Pharmacotherapy. 2016;36(2):196-202.
8. Campbell NL, Perkins AJ, Bradt P, Perk S, Wielage R, Boustani M, Ng D. The association of anticholinergic burden with cognitive impairment and healthcare utilization. Pharmacotherapy 2016;36(11):1123-1131.
9. AGS/NIA Delirium Conference Writing Group, Planning Committee and Faculty. The American Geriatrics Society/National Institute on Aging Bedside-to-Bench Conference: Research Agenda on Delirium in Older Adults. J Am Geriatr Soc 2015; doi: 10.1111/jgs.13406.
10. Campbell NL, Skaar T, Perkins AJ, Gao S, Li L, Khan BA, Boustani MA. Characterization of Hepatic Enzyme Activity in Older Adults with Dementia: Potential Impact on Personalizing Pharmacotherapy. Clin Interv Aging 2015; 10:269-275.